JP2020506162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506162A5 JP2020506162A5 JP2019523734A JP2019523734A JP2020506162A5 JP 2020506162 A5 JP2020506162 A5 JP 2020506162A5 JP 2019523734 A JP2019523734 A JP 2019523734A JP 2019523734 A JP2019523734 A JP 2019523734A JP 2020506162 A5 JP2020506162 A5 JP 2020506162A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- item
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091035707 Consensus sequence Proteins 0.000 claims description 48
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 description 60
- 238000000034 method Methods 0.000 description 43
- 108010025628 Apolipoproteins E Proteins 0.000 description 25
- 102000013918 Apolipoproteins E Human genes 0.000 description 25
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 9
- 230000008021 deposition Effects 0.000 description 7
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 102000053020 human ApoE Human genes 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 1
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164847A JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
| JP2024193660A JP2025023998A (ja) | 2016-10-28 | 2024-11-05 | 抗ａｐｏｅ抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414413P | 2016-10-28 | 2016-10-28 | |
| US62/414,413 | 2016-10-28 | ||
| US201762533336P | 2017-07-17 | 2017-07-17 | |
| US62/533,336 | 2017-07-17 | ||
| PCT/US2017/058874 WO2018081642A1 (en) | 2016-10-28 | 2017-10-27 | Anti-apoe antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164847A Division JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506162A JP2020506162A (ja) | 2020-02-27 |
| JP2020506162A5 true JP2020506162A5 (enExample) | 2021-02-04 |
| JP7236737B2 JP7236737B2 (ja) | 2023-03-10 |
Family
ID=62024064
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523734A Active JP7236737B2 (ja) | 2016-10-28 | 2017-10-27 | 抗ａｐｏｅ抗体 |
| JP2022164847A Pending JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
| JP2024193660A Pending JP2025023998A (ja) | 2016-10-28 | 2024-11-05 | 抗ａｐｏｅ抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164847A Pending JP2022191397A (ja) | 2016-10-28 | 2022-10-13 | 抗ａｐｏｅ抗体 |
| JP2024193660A Pending JP2025023998A (ja) | 2016-10-28 | 2024-11-05 | 抗ａｐｏｅ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US11124562B2 (enExample) |
| EP (1) | EP3532034A4 (enExample) |
| JP (3) | JP7236737B2 (enExample) |
| AU (2) | AU2017350947B2 (enExample) |
| CA (1) | CA3042236A1 (enExample) |
| WO (1) | WO2018081642A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11124562B2 (en) | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
| US20220296707A1 (en) * | 2019-06-04 | 2022-09-22 | Regents Of The University Of Minnesota | Anti-opioid compounds and methods of making and using same |
| CN112538113B (zh) * | 2020-08-06 | 2023-07-21 | 武汉天德生物科技有限公司 | 杂交瘤细胞株ace8及其产生的apoe4点突变单克隆抗体 |
| EP4204003A4 (en) * | 2020-08-28 | 2024-08-21 | Board of Regents, The University of Texas System | ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| WO2023069892A1 (en) * | 2021-10-19 | 2023-04-27 | Short Jay M | Conditionally active proteins for neurodegenerative diseases |
| WO2025049995A1 (en) * | 2023-09-01 | 2025-03-06 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Anti-ly6 antibodies and uses thereof |
| WO2025219956A1 (en) | 2024-04-18 | 2025-10-23 | Comed Therapeutics Ltd. | Compositions and methods for rna delivery to cells |
| CN118184783B (zh) * | 2024-05-09 | 2024-07-09 | 成都微芯新域生物技术有限公司 | Hla-g抗体及其制备方法和用途 |
| CN119147750A (zh) * | 2024-11-15 | 2024-12-17 | 科美诊断技术股份有限公司 | 一种apoe4的光激化学发光检测试剂、试剂盒及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US6313089B1 (en) | 1997-08-20 | 2001-11-06 | Duke University | Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use |
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| WO2001072307A1 (en) * | 2000-03-29 | 2001-10-04 | The J. David Gladstone Institutes | Methods of treating cognitive decline disease conditions with androgens |
| US7754433B2 (en) * | 2001-12-03 | 2010-07-13 | Amgen Fremont Inc. | Identification of high affinity molecules by limited dilution screening |
| GB0200757D0 (en) * | 2002-01-15 | 2002-02-27 | Univ Manchester | Diagnostic methods |
| AR047729A1 (es) | 2003-11-28 | 2006-02-15 | Astrazeneca Ab | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) |
| CA2672049C (en) | 2006-12-08 | 2016-05-10 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| DE102009047243A1 (de) * | 2009-11-27 | 2011-06-01 | Orgentec Diagnostika Gmbh | Monospezifische Polypeptidreagenzien |
| US9102717B2 (en) * | 2010-03-01 | 2015-08-11 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| RU2013130002A (ru) | 2010-12-02 | 2015-01-10 | Дзе Вашингтон Юниверсити | Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками |
| JP2014511174A (ja) * | 2011-02-07 | 2014-05-15 | ネオトープ バイオサイエンシーズ リミテッド | Ａｐｏｅ免疫療法 |
| CA2859808A1 (en) | 2011-12-19 | 2013-06-27 | The Washington University | Methods for diagnosing alzheimer's disease |
| US20150140672A1 (en) | 2011-12-19 | 2015-05-21 | Washington University | Methods for detecting amyloid beta amyloidosis |
| WO2013168174A1 (en) | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| CA2890758A1 (en) | 2012-11-20 | 2014-05-30 | Washington University | Methods of diagnosing amyloid pathologies using analysis of amyloid-beta enrichment kinetics |
| WO2015187992A2 (en) * | 2014-06-05 | 2015-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
| US20170218058A1 (en) | 2016-01-28 | 2017-08-03 | Alector, LLC | Anti-apoe4 antigen-binding proteins and methods of use thereof |
| US11124562B2 (en) * | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
-
2017
- 2017-10-27 US US16/345,637 patent/US11124562B2/en active Active
- 2017-10-27 JP JP2019523734A patent/JP7236737B2/ja active Active
- 2017-10-27 EP EP17865058.6A patent/EP3532034A4/en active Pending
- 2017-10-27 CA CA3042236A patent/CA3042236A1/en active Pending
- 2017-10-27 AU AU2017350947A patent/AU2017350947B2/en active Active
- 2017-10-27 WO PCT/US2017/058874 patent/WO2018081642A1/en not_active Ceased
-
2021
- 2021-08-24 US US17/410,686 patent/US11926660B2/en active Active
-
2022
- 2022-10-13 JP JP2022164847A patent/JP2022191397A/ja active Pending
-
2024
- 2024-02-08 US US18/436,678 patent/US20240309077A1/en active Pending
- 2024-05-10 AU AU2024203123A patent/AU2024203123A1/en active Pending
- 2024-11-05 JP JP2024193660A patent/JP2025023998A/ja active Pending
- 2024-11-08 US US18/942,122 patent/US20250145697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506162A5 (enExample) | ||
| AU2021202095B2 (en) | Use of semaphorin-4D binding molecules for treating neurodegenerative disorders | |
| JP2006516116A5 (enExample) | ||
| JP6218810B2 (ja) | 卒中後の神経形成を促進するためのセマフォリン−４ｄ結合分子の使用 | |
| JP7236737B2 (ja) | 抗ａｐｏｅ抗体 | |
| JP2022500081A (ja) | 抗ｔｒｅｍ−２アゴニスト抗体 | |
| JP2010526028A5 (enExample) | ||
| ZA200500068B (en) | Treatment of tnf related disorders | |
| ES2662100T3 (es) | Anticuerpos humanos y diagnósticos y usos terapéuticos de los mismos para el tratamiento de la enfermedad neurológica | |
| JP2017523140A5 (enExample) | ||
| JP2009530423A5 (enExample) | ||
| JP2016518411A5 (enExample) | ||
| JP6379113B2 (ja) | 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 | |
| RU2016151179A (ru) | Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента | |
| Muso et al. | Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan | |
| JP6868015B2 (ja) | 母性脳反応性抗体に対するおとり抗原を使用する自閉スペクトラム症の抑制 | |
| JP7610767B2 (ja) | レット症候群の処置のためのセマフォリン４ｄ結合分子の使用 | |
| US20130336961A1 (en) | B Cell Depletion for Central Nervous System Injuries and Methods and Uses Thereof | |
| Warrington et al. | Regeneration strategies for multiple sclerosis |